Impact of Demographics and Insurance Coverage on Schizophrenia Treatment and Healthcare Resource Utilization Within an Integrated Healthcare System
Sanghyuk Seo,Bridget Healey,Ronae McLin,Naomi Sacks,Carmela Benson,Leslie Citrome
DOI: https://doi.org/10.2147/ndt.s473492
IF: 2.989
2024-09-27
Neuropsychiatric Disease and Treatment
Abstract:Sanghyuk Seo, 1 Bridget E Healey, 2 Ronae McLin, 2 Naomi C Sacks, 2 Carmela J Benson, 1 Leslie Citrome 3 1 Medical Affairs Neuroscience, Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Titusville, NJ, USA; 2 PRECISIONheor, Boston, MA, USA; 3 Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA Correspondence: Carmela J Benson, Medical Affairs Neuroscience, Johnson & Johnson Innovative Medicine, 1125 Trenton Harbourton Road, Titusville, NJ, 08560, USA, Email Purpose: Little is known about the impact of health disparities on antipsychotic treatment and healthcare resource utilization (HRU) among patients with schizophrenia. The objective of this analysis is to examine treatment patterns and HRU by age, race/ethnicity, and insurance coverage among patients with schizophrenia in an integrated delivery network (IDN). Patients and Methods: This cross-sectional study used electronic health record data from MedStar Health, an IDN in the Baltimore-Washington, DC, area. Patients were aged ≥ 18 years and had ≥ 2 outpatient encounters or ≥ 1 hospitalization with a diagnosis of schizophrenia between January 1, 2017 and March 31, 2021. Outcomes assessed included oral antipsychotic prescriptions, long-acting injectable antipsychotic (LAI) utilization, hospitalizations, emergency department (ED) visits, and outpatient visits. Analyses compared subgroups based on age, race/ethnicity (non-Hispanic Black, non-Hispanic White, and other), and type of insurance coverage at index (Medicare, Medicaid, and other) during 12 months of follow-up. Results: A total of 78.1% of patients had ≥ 1 prescription for an antipsychotic and 69.1% received ≥ 1 second-generation antipsychotic. Second-generation long-acting injectables (SGA LAI) were utilized by 9.0% of patients, with the elderly and Medicaid beneficiaries having the lowest SGA LAI utilization. Overall, 61.7% of patients had ≥ 1 hospitalization, 56.4% had ≥ 1 outpatient visit, and 50.5% had ≥ 1 ED visit. Hospitalizations and ED visits were most common in those 18 to 24 years of age and in Medicaid beneficiaries, whereas outpatient visits were more common for the elderly and Medicare beneficiaries. Conclusion: At the population level, the results indicate widespread underprescription/underutilization of antipsychotics that have been shown to improve clinical and economic outcomes in patients with schizophrenia, particularly SGA LAI. Within specific subpopulations, disparities in treatment selection and HRU were observed, suggesting the need for increased attention to at-risk groups to ensure consistent quality of care regardless of age, race/ethnicity, or insurance coverage. Keywords: health disparities, race/ethnicity, antipsychotic prescription, long-acting injectable antipsychotics, second-generation antipsychotic, clinical outcomes Schizophrenia is a complex psychiatric disorder that resulted in an estimated economic burden of $343.2 billion in 2019. 1 This disorder significantly raises the risk of mortality compared to the general population, resulting in approximately 28.5 years of life lost per patient. 2 Goals of therapy in patients with schizophrenia are individualized and may include avoiding relapses, improving social functioning, and maximizing quality of life. At a population level, medication adherence, avoidance of the use of acute care services such as hospitals and emergency departments (EDs), and appropriate follow-up of patients after acute events have been identified as key indicators of quality of care. 3–7 Recommendations to achieve these measures include the use of long-acting injectable (LAI) antipsychotics and providing patient care in the least restrictive setting that will allow for safe and effective treatment. Social determinants of health such as race, socioeconomic status, and geographic location are key contributors to the incidence and burden of schizophrenia. 8–11 The burden of disease in patients with schizophrenia is further complicated by frequent gaps in insurance coverage, 12 poor health literacy, 13 and substantial non-psychiatric and psychiatric comorbidities, including alcohol and substance misuse. 14,15 As such, the psychiatric community has advocated for serious mental illness to be designated as a health disparity in efforts to facilitate its prioritization as a public health effort. 16,17 Differences in antipsychotic prescriptions and healthcare resource utilization (HRU) based on race and ethnicity have been previously identified from real-world studies; however, less is known about the influence of age and insurance cover -Abstract Truncated-
psychiatry,clinical neurology